Annals of Oncology Advance Access originally published online on February 9, 2006
Annals of Oncology 2006 17(4):571-577; doi:10.1093/annonc/mdl007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-
2b in metastatic melanoma
1 Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; 2 Unit of Medical Oncology A, Istituto Nazionale Tumori Fondazione Pascale, Naples; 3 Unit of Medical Oncology, National Cancer Research Institute, Genoa; 4 University of Genoa, 5 Institute of Dermatology, University of Turin; 6 Melanoma Center, St. Luke's Episcopal Hospital, Houston (USA); 7 Scientific Director, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
* Correspondence to: Dr E. Bajetta, Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. Tel: +39-02-23902500; Fax: +39-02-23902149; E-mail: emilio.bajetta{at}istitutotumori.mi.it
Background: The addition of cytokines to chemotherapy (CT) has obtained encouraging but contradictory results in metastatic melanoma. In this phase III trial, we compared the effects of CT [cisplatin, vindesine and dacarbazine (CVD)] with those of concurrent biochemotherapy (bioCT) consisting of CVD plus interleukin-2 and interferon-
2b.
Patients and methods: A total of 151 untreated metastatic melanoma patients were randomized, 75 on arm A (cisplatin 30 mg/m2 on days 1–3, vindesine 2.5 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 1–3), and 76 on arm B (same CVD scheme plus interferon-2b on days 1–5 and interleukin-2 on days 1–5 and 8–15, both administered subcutaneously), either recycled every 3 weeks. Response was assessed every two cycles.
Results: Ten percent of the patients were alive at a median of 52 months from start of therapy. We observed a response rate (RR) of 21% on arm A versus 33% on arm B; three patients (4%) given bioCT had complete responses (CRs). Median time to progression (TTP) was identical; median overall survival (OS) time was 12 months on arm A and 11 months on arm B.
Conclusions: BioCT is not better than CT alone; the trend in favor of the bioCT in terms of RR did not translate into better TTP or OS. Therefore, bioCT cannot be recommended as standard first-line therapy for metastatic melanoma.
Key words: chemotherapy, cytokines, immunotherapy, metastatic melanoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. R. Minor, D. Moore, C. Kim, M. Kashani-Sabet, S. S. Venna, W. Wang, P. Boasberg, and S. O'Day Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy Oncologist, October 1, 2009; 14(10): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schadendorf, S. M. Algarra, L. Bastholt, G. Cinat, B. Dreno, A. M. M. Eggermont, E. Espinosa, J. Guo, A. Hauschild, T. Petrella, et al. Immunotherapy of distant metastatic disease Ann. Onc., August 1, 2009; 20(suppl_6): vi41 - vi50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Atkins, J. Hsu, S. Lee, G. I. Cohen, L. E. Flaherty, J. A. Sosman, V. K. Sondak, and J. M. Kirkwood Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., December 10, 2008; 26(35): 5748 - 5754. [Abstract] [Full Text] [PDF]
|
|